Website: N/A
Stock Symbol: NASDAQ: IMMU
Market Value: N/A (in millions)
Immunomedics is a New Jersey-based biopharmaceutical company focused on the
development of monoclonal antibody-based products for the targeted treatment of
cancer, autoimmune and other serious diseases. We have developed a number of
advanced proprietary technologies that allow us to create humanized antibodies
that can be used either alone in unlabeled or “naked” form, or conjugated with
radioactive isotopes, chemotherapeutics or toxins, in each case to create highly
targeted agents. Using these technologies, we have built a pipeline of
therapeutic product candidates that utilize several different mechanisms of
action. We have licensed our lead product candidate, epratuzumab, to UCB, S.A.,
or UCB, for the treatment of all autoimmune disease indications worldwide. We
have retained the rights for epratuzumab in oncology indications for which UCB
has been granted a buy-in option.